DRIVE-SHIFT: Modest Weight Gain Observed Through Wk 144 After Switch to DOR/3TC/TDF in Virologically Suppressed Adults

July 6-10, 2020; Virtual
More than 2 years after the switch to DOR/3TC/TDF, adjusted mean weight gains ranged from 1.2-1.4 kg with no evident differences by sex, race, or ethnicity. The majority of patients (~ 70%) experienced < 5% weight gain at Week 144 of the study.
Format: Microsoft PowerPoint (.ppt)
File Size: 240 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

person default Anonymous Patient Released: January 11, 2022

From Clinical Care Options (CCO) and Dr. Jürgen K. Rockstroh and Dr. Giada Sebastiani: Recommended approach for screening and diagnosing NASH in patients with HIV.

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 10, 2022 Expired: January 9, 2023

Expert insight on treatment strategies for NASH in patients living with HIV, from Clinical Care Options (CCO)

Jürgen K. Rockstroh, MD Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 10, 2022 Expired: January 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings